Literature DB >> 26498247

A cryptic paracentric inversion of MSH2 exons 2-6 causes Lynch syndrome.

Qing Liu1, Luke B Hesson1, Andrea C Nunez1, Deborah Packham1, Rachel Williams2, Robyn L Ward3,4, Mathew A Sloane1.   

Abstract

Lynch syndrome is an autosomal dominant disorder that predisposes carriers of DNA mismatch repair (MMR) gene mutations to early-onset cancer. Germline testing screens exons and splice sites for mutations, but does not examine introns or RNA transcripts for alterations. Pathogenic mutations have not been detected in ~30% of suspected Lynch syndrome cases with standard screening practices. We present a 38-year-old male with a clinicopathological and family history consistent with Lynch syndrome, including loss of MSH2 expression in his tumor. Germline testing revealed normal MSH2 coding sequence, splice sites and exon copy number, however, cDNA sequencing identified an aberrant MSH2 transcript lacking exons 2-6. An inversion PCR on germline DNA identified an ~18kb unbalanced, paracentric inversion within MSH2, with breakpoints in a long terminal repeat in intron 1 and an Alu repeat in intron 6. The 3' end of the inversion had a 1.2 kb deletion and an 8 bp insertion at the junction with intron 6. Screening of 55 additional Australian patients presenting with MSH2-deficient tumors who were negative in germline genetic tests for MSH2 mutations identified another inversion-positive patient. We propose an Alu-mediated recombination model to explain the origin of the inversion. Our study illustrates the potential value of cDNA screening to identify patients with cryptic MMR gene rearrangements, clarifies why standard testing may not detect some pathogenic alterations, and provides a genetic test for screening individuals with suspected Lynch syndrome that present with unexplained MSH2-deficient tumors.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26498247     DOI: 10.1093/carcin/bgv154

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  13 in total

1.  Identification of MSH2 inversion of exons 1-7 in clinical evaluation of families with suspected Lynch syndrome.

Authors:  Maureen E Mork; Andrea Rodriguez; Melissa W Taggart; Miguel A Rodriguez-Bigas; Patrick M Lynch; Sarah A Bannon; Y Nancy You; Eduardo Vilar
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

2.  Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics.

Authors:  Monika Morak; Verena Steinke-Lange; Trisari Massdorf; Anna Benet-Pages; Melanie Locher; Andreas Laner; Katrin Kayser; Stefan Aretz; Elke Holinski-Feder
Journal:  Fam Cancer       Date:  2020-04       Impact factor: 2.375

3.  Detecting inversions in routine molecular diagnosis in MMR genes.

Authors:  Edwige Kasper; Sophie Coutant; Sandrine Manase; Stéphanie Vasseur; Pierre Macquère; Gaëlle Bougeard; Laurence Faivre; Olivier Ingster; Stéphanie Baert-Desurmont; Claude Houdayer
Journal:  Fam Cancer       Date:  2022-01-08       Impact factor: 2.375

Review 4.  Hereditary Nonpolyposis Colorectal Cancer and Cancer Syndromes: Recent Basic and Clinical Discoveries.

Authors:  Erbao Chen; Xiaojing Xu; Tianshu Liu
Journal:  J Oncol       Date:  2018-04-23       Impact factor: 4.375

Review 5.  How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies.

Authors:  Richard Gallon; Peter Gawthorpe; Rachel L Phelps; Christine Hayes; Gillian M Borthwick; Mauro Santibanez-Koref; Michael S Jackson; John Burn
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

Review 6.  Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors.

Authors:  Julie Leclerc; Catherine Vermaut; Marie-Pierre Buisine
Journal:  Cancers (Basel)       Date:  2021-01-26       Impact factor: 6.639

7.  Genetic testing for inherited colorectal cancer and polyposis, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Rong Mao; Patti Krautscheid; Rondell P Graham; Arupa Ganguly; Suma Shankar; Matthew Ferber; Madhuri Hegde
Journal:  Genet Med       Date:  2021-06-17       Impact factor: 8.822

8.  Germline and Tumor Sequencing as a Diagnostic Tool To Resolve Suspected Lynch Syndrome.

Authors:  Bernard J Pope; Mark Clendenning; Christophe Rosty; Khalid Mahmood; Peter Georgeson; Jihoon E Joo; Romy Walker; Ryan A Hutchinson; Harindra Jayasekara; Sharelle Joseland; Julia Como; Susan Preston; Amanda B Spurdle; Finlay A Macrae; Aung K Win; John L Hopper; Mark A Jenkins; Ingrid M Winship; Daniel D Buchanan
Journal:  J Mol Diagn       Date:  2020-12-29       Impact factor: 5.568

9.  Cytoplasmic MSH2 Related to Genomic Deletions in the MSH2/EPCAM Genes in Colorectal Cancer Patients With Suspected Lynch Syndrome.

Authors:  Lin Dong; Shuangmei Zou; Xianglan Jin; Haizhen Lu; Ye Zhang; Lei Guo; Jianqiang Cai; Jianming Ying
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

Review 10.  Germline Structural Variations in Cancer Predisposition Genes.

Authors:  Tímea Pócza; Vince Kornél Grolmusz; János Papp; Henriett Butz; Attila Patócs; Anikó Bozsik
Journal:  Front Genet       Date:  2021-04-14       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.